Gavin A Lewis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/839671/publications.pdf

Version: 2024-02-01

18 papers	396 citations	1478505 6 h-index	11 g-index
19	19	19	772
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2186-2200.	2.8	159
2	Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1477-1482.	30.7	92
3	Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial. Cardiovascular Drugs and Therapy, 2019, 33, 461-470.	2.6	48
4	Improving Safety in Catheter Ablation for Atrial Fibrillation: A Prospective Study of the Use of Ultrasound to Guide Vascular Access. Journal of Cardiovascular Electrophysiology, 2014, 25, 680-685.	1.7	38
5	Cholecystectomy in patients with prior ventriculoperitoneal shunts. American Journal of Surgery, 2011, 201, 503-507.	1.8	19
6	Considerations for Clinical Trials Targeting the Myocardial Interstitium. JACC: Cardiovascular Imaging, 2019, 12, 2319-2331.	5.3	12
7	Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation study. The Lancet Digital Health, 2022, 4, e445-e454.	12.3	8
8	Atrial fibrillation during pregnancy: cardioversion with flecainide. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 720-721.	0.5	6
9	The utility of cardiovascular imaging in heart failure with preserved ejection fraction: diagnosis, biological classification and risk stratification. Heart Failure Reviews, 2021, 26, 661-678.	3.9	4
10	Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2022, 15, 1436-1443.	2.4	4
11	Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2022, 38, 1569-1578.	1.5	2
12	Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. Journal of the American Heart Association, 0 , , .	3.7	2
13	7 Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction. , 2021, , .		1
14	Pulmonary embolism and patent foramen ovale causing an ischaemic stroke. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 592-593.	0.5	0
15	11â€First, Do No Harm. Improving Safety in Catheter Ablation for Atrial Fibrillation: A Prospective Study of the Use of Ultrasound to Guide Vascular Access. Heart, 2014, 100, A5.2-A6.	2.9	O
16	Letter by Lewis and Miller Regarding Article, "Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure With Preserved Ejection Fraction― Circulation, 2017, 135, e679-e680.	1.6	0
17	009â€The effect of cardiac magnetic resonance on human circulating leukocytes. Heart, 2017, 103, A7.2-A8.	2.9	O
18	Beyond Valvular Heart Disease. Journal of the American College of Cardiology, 2020, 75, 317-319.	2.8	0